Otsuka, Lundbeck's Rxulti get positive opinion in EU from CHMP to treat schizophrenia in adults

Otsuka Pharmaceutical Co., Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion on Rxulti

More From BioPortfolio on "Otsuka, Lundbeck's Rxulti get positive opinion in EU from CHMP to treat schizophrenia in adults"